In This Article:
YANTAI, China, April 9, 2025 /PRNewswire/ -- On April 8, 2025 (UTC-7), impressive results of the Phase 3 clinical trial (NCT05737160) evaluating the efficacy and safety of Telitacicept (synonym: RC18; brand name: 泰爱®) in patients with generalized myasthenia gravis (gMG) were presented during the Late-Breaking Science Session at the American Academy of Neurology (AAN) Annual Meeting 2025 in San Diego, CA.
According to the presented data, among the participants in the Telitacicept 240 mg group, 98.1% of the patients demonstrated a ≥ 3-point reduction in Myasthenia Gravis Activities of Daily Living (MG-ADL) score and 87% of the patients demonstrated a ≥ 5-point reduction in Quantitative Myasthenia Gravis (QMG) score at Week 24. With the highest MG-ADL response rate among all drugs for gMG with phase 3 studies reported to date, Telitacicept will provide an important new treatment option gMG.
Telitacicept is a novel fusion protein targeting both BlyS and APRIL independently designed and developed by RemeGen Co.,Ltd. ("RemeGen"). The multicenter, randomized, double-blind, placebo-controlled phase 3 clinical trial was conducted in China (NCT05737160) and led by Professor Jian Yin of Beijing Hospital. A total of 114 gMG patients with baseline MG-ADL score ≥6 and QMG score ≥8 were enrolled in the study, with 57 patients in the Telitacicept 240 mg group and the placebo group respectively. The study consisted of a 24-week double-blind treatment stage and an open-label treatment stage. The presented results herein were from the double-blind treatment study.
The data showed that Telitacicept achieved sustained and significant improvement in clinical outcomes for patients with gMG, with a favorable safety profile：
-
Telitacicept demonstrated significant improvements in MG-ADL and QMG scores after 4 weeks' treatment compared to placebo.
-
At Week 24, change in MG-ADL was -5.74 and -0.91 with Telitacicept and placebo group, respectively. 98.1% and 12.0% of Telitacicept and placebo group patients had ≥3-point reduction in MG-ADL, respectively. The MG-ADL scale quantifies the impact of MG symptoms on daily life quality, focusing on patients' subjective experience and daily function. These data showed that patients treated with Telitacicept achieved clinically meaningful improvement.
-
At Week 24, change in QMG was -8.66 and -2.27 with Telitacicept and placebo group, respectively. 87.0% and 16.0% of Telitacicept and placebo group patients had ≥ 5-point reduction in QMG, respectively. The QMG score assesses the strength and endurance of the whole body muscle group, focusing on objective measurement. These data demonstrated that patients treated with Telitacicept achieved clinically meaningful reductions in disease severity. There is a strong correlation between MG-ADL and QMG in evaluating treatment response, and the combination of MG-ADL and QMG can comprehensively reflect the disease severity.
-
Sustained improvement: MG-ADL and QMG scores continued to decline over time in the Telitacicept group, with peak improvement at the last reported observation, Week 24.
-
Telitacicept was well tolerated during the treatment, with an overall adverse event (AE) incidence similar to that in the placebo group and an incidence of infection-related AEs lower than that in the placebo group (45.6% vs. 59.6%).